Background: Breast milk has been used to feed extremely preterm infants since the 1990s after breast milk was widely recommended as the primary food source for all high risk infants. Breast milk is now the most commonly prescribed first enteral feed in the NICU environment and breastfeeding is strongly encouraged. The aim of this study was to compare neurodevelopmental outcomes of <29 week preterm infants at corrected age 2-3 years between breast milk fed and formula fed infants.
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Methods: A regional cohort study was performed of infants born at 23 to 28 weeks gestation and admitted to the NICUs of NSW and ACT from 2007-2012. Infants were categorised by type of milk intake at the time of discharge. The primary outcome was incidence of moderate to severe neurosensory impairment at 2 to 3 years corrected age, defined as developmental delay (2 SD below the mean), cerebral palsy, bilateral deafness or bilateral blindness.
Results: Of 1514 survivors assessed, the incidence of moderate to severe neurodevelopmental impairment was 7% v 16% (OR 0.43; 95% CI 0.33-0.54) and cerebral palsy was 5% v 10% (OR 0.52; 95% CI 0.33-0.80) in breast milk fed and formula fed groups respectively. On multivariate analysis, the incidence of any moderate to severe neurosensory impairment was lower in the breast milk fed group compared with formula and mixed feeding groups (23% v 40% [aOR 0.48; 95% CI 0.34-0.69]).
Conclusions: Breast milk fed infants had significantly better neurodevelopmental outcomes compared to formula or mixed feeding infants. This highlights the importance of continuing to focus on encouraging exclusive breast milk use and breastfeeding in this vulnerable population. Indigenous Australians are twice as likely as non-Indigenous Australians to develop chronic kidney disease (CKD). We hypothesise that this renal dysfunction may originate from impaired fetal renal development due to exposure to an obesogenic intrauterine environment. The aim of our study was to examine whether there was an association between maternal adiposity and fetal kidney growth in late gestation.
THE RELATIONSHIP BETWEEN MATERNAL ADIPOSITY DURING PREGNANCY AND FETAL KIDNEY DEVELOPMENT IN UTERO IN AN INDIGENOUS AUSTRALIAN PREGNANCY-THROUGH-TO-EARLY-
Methods: 147 Indigenous mother-child pairs from the Gomeroi gaaynggal study were examined. Fetal kidney structural parameters were assessed by ultrasound. Pre-pregnancy body mass index (BMI) was recorded at first visit and maternal adiposity during late pregnancy was assessed using percent body fat and visceral fat area obtained via bioelectrical impedance analysis (BIA) method. Multiple linear regression models were used and sensitivity analyses were carried out to determine the covariates to be adjusted for.
Results: Maternal adiposity and pre-pregnancy BMI were positively associated with estimated fetal weight (EFW) in late fetal life. When adjusted for smoking, maternal percentage body fat was negatively associated with combined kidney volume relative to EFW. Maternal adiposity and pre-pregnancy BMI were not associated with fetal kidney size.
Conclusions: Our study shows that in late pregnancy, maternal adiposity is associated with increased fetal weight but not fetal kidney size. Consequently, maternal adiposity is associated with a reduction in fetal kidney volume relative to EFW. Our findings suggest that Indigenous babies born to obese mothers are already experiencing glomerular hyperfiltration in utero due to possibly fewer nephrons relative to body weight, predisposing them to higher risk of CKD in later life. Background: Despite advances in treatment of type 1 diabetes, pregnancy outcomes remain suboptimal with one-in-two being complicated by pre-term delivery, large-for-gestational-age infants and neonatal intensive-care admissions. Outside of pregnancy, the artificial pancreas has demonstrated improvements in glycaemic control. Our group has performed two proof-ofconcept trials, demonstrating the efficacy and safety of the device during pregnancy, but revealing significant variability in glycaemic responses.
FACTORS IMPROVING OUTCOMES OF THE ARTIFICIAL
Method: This pre-specified secondary analysis examined data from the previous two trials (n=32) to assess factors that predict women's responses to the technology. The primary endpoint was a composite outcome (a positive biomedical response and/or psychosocial response). A positive psychosocial response was defined as an improvement in participants' attitude to the technology from their baseline qualitative interview to their follow-up interview. The effects of multiple variables on device efficacy was examined using qualitative and quantitative analyses.
